Determine if Either of 2 Doses of Study Drug Given With a Low-dose of Cyclophosphamide After a Complete or Partial Response to a Platinum-based Second-line Therapy in Women With Recurrent Ovarian Carcinoma Results in a Longer Time to Progression When Compared to the First Time to Progression.
- First Posted Date
- 2006-12-08
- Last Posted Date
- 2017-08-18
- Lead Sponsor
- EMD Serono
- Registration Number
- NCT00408967
ATS-1 Needle Free Injection Device Study-a Device for Administering r-hGH (Saizen) to Treat Growth Hormone Deficiency
Phase 1
Completed
- Conditions
- First Posted Date
- 2006-12-05
- Last Posted Date
- 2013-10-22
- Lead Sponsor
- EMD Serono
- Target Recruit Count
- 38
- Registration Number
- NCT00407472
AS703569 Phase I in Patients With Solid Tumours
- First Posted Date
- 2006-10-24
- Last Posted Date
- 2014-01-30
- Lead Sponsor
- EMD Serono
- Target Recruit Count
- 104
- Registration Number
- NCT00391521
- Locations
- 🇺🇸
EMD Serono Medical Information Office, Rockland, Massachusetts, United States
Rebif® Pregnancy Registry
Completed
- Conditions
- First Posted Date
- 2006-06-20
- Last Posted Date
- 2013-08-05
- Lead Sponsor
- EMD Serono
- Target Recruit Count
- 36
- Registration Number
- NCT00338741
- Locations
- 🇺🇸
Local Medical Information Office, Rockland, Massachusetts, United States
Luveris® (Lutropin Alfa for Injection) in Women With Hypogonadotropic Hypogonadism (Luteinizing Hormone [LH] Less Than [<] 1.2 International Unit Per Liter [IU/L])
- First Posted Date
- 2006-05-24
- Last Posted Date
- 2013-08-07
- Lead Sponsor
- EMD Serono
- Target Recruit Count
- 11
- Registration Number
- NCT00328926
- Locations
- 🇺🇸
U.S. Medical Information, 1-888-275-7376, Rockland, Massachusetts, United States
Sarizotan in Parkinson Patients With L-dopa-induced Dyskinesia
Phase 2
Completed
- Conditions
- First Posted Date
- 2006-04-13
- Last Posted Date
- 2017-01-23
- Lead Sponsor
- EMD Serono
- Target Recruit Count
- 360
- Registration Number
- NCT00314288
Safety and Efficacy of Treatment With Interferon Beta-1a Rebif® in Patients With Crohn's Disease
Phase 2
Terminated
- Conditions
- First Posted Date
- 2006-03-17
- Last Posted Date
- 2013-08-06
- Lead Sponsor
- EMD Serono
- Target Recruit Count
- 192
- Registration Number
- NCT00304252
- Locations
- 🇬🇧
Medical Information Office, Feltham, United Kingdom
Safety and Efficacy of Interferon-Beta-1a (Rebif®) for Treating Subjects With Acute Symptoms of Ulcerative Colitis
Phase 2
Completed
- Conditions
- Interventions
- First Posted Date
- 2006-03-16
- Last Posted Date
- 2013-08-06
- Lead Sponsor
- EMD Serono
- Target Recruit Count
- 194
- Registration Number
- NCT00303381
- Locations
- 🇬🇧
Research Site, Feltham, United Kingdom
A Study to Compare the Safety and Efficacy of Cetrotide® 3 Milligram (mg) Versus Antagon™ in Women Undergoing Ovarian Stimulation
- First Posted Date
- 2006-03-01
- Last Posted Date
- 2014-03-26
- Lead Sponsor
- EMD Serono
- Target Recruit Count
- 185
- Registration Number
- NCT00298025
An Efficacy and Safety Trial of Serostim® in the Maintenance of the Treatment Effect Obtained During the Study of Serostim® in Human Immunodeficiency Virus-associated Adipose Redistribution Syndrome
Phase 2
Completed
- Conditions
- Interventions
- First Posted Date
- 2006-02-22
- Last Posted Date
- 2014-03-26
- Lead Sponsor
- EMD Serono
- Target Recruit Count
- 142
- Registration Number
- NCT00294918
© Copyright 2024. All Rights Reserved by MedPath